

## ASX Release

---

# Dr Reuben Benjamin Appointed to SUDA's iNKT Cell Therapy Scientific Advisory Board

- SUDA enhances its Scientific Advisory Board (SAB) to gain expert guidance on the clinical development of allogenic cell therapies
- Dr Reuben Benjamin, who leads the plasma cell disorder service and CAR-T cell programme at King's College, joins SUDA's SAB for the invariant Natural Killer T cell (iNKT) platform

**PERTH, AUSTRALIA – 26 August 2021:** SUDA Pharmaceuticals Ltd (ASX: SUD), a biotechnology company focused on developing therapies to treat cancer and conditions that affect the central nervous system, has appointed Dr Reuben Benjamin to its Scientific Advisory Board for the iNKT cell therapy platform.

Dr Benjamin is an internationally recognised expert in the field of cellular immunotherapies for the treatment of blood cancer. At King's College London, UK, Dr Benjamin leads the plasma cell disorder service and CAR-T cell programme. He is also a Consultant Haematologist and Honorary Senior Lecturer with an interest in multiple myeloma, stem cell transplantation and cell therapy. Dr Benjamin has an active research group at King's College London focusing on allogeneic CAR-T cells for lymphoid malignancies as well as in studying the biology of extramedullary myeloma.

Dr Benjamin was the Chief Investigator of the CALM clinical trial, the first allogeneic (off-the-shelf) CAR-T cell study for relapsed adult B-cell acute lymphoblastic leukemia (B-ALL) and he was the lead author for the research paper published in Lancet in December 2020. Dr Benjamin is actively involved in offering CAR-T cell therapy for myeloma and lymphoma.

SUDA is committed to developing its iNKT cell therapy platform, initially for the treatment of blood cancers. A key advantage of iNKT cells is that they are anticipated to be used off-the-shelf, having been shown to be protective against graft versus host disease (GVHD). GVHD is a side effect that limits conventional cell therapy treatments from being produced from a healthy donor.

SUDA's CEO and MD, Dr Michael Baker, commented "To strengthen our ability to develop the iNKT cell therapy platform for off-the-shelf use, we have sought the involvement of leaders in the field. Dr Benjamin has tremendous experience developing cell therapies and having input from the Chief Investigator of the first off-the-shelf clinical trial for B-ALL will

provide invaluable expertise to SUDA as we continue to develop our iNKT cell therapy platform.”

For and on behalf of the Board and for further information, please contact:

**Dr Michael Baker**

**Chief Executive Officer & Managing Director**

**SUDA Pharmaceuticals Ltd**

Tel +61 (0) 403 468 187

mbaker@sudapharma.com

## **NOTES TO EDITORS:**

### **About SUDA Pharmaceuticals Ltd**

SUDA Pharmaceuticals Ltd (ASX: SUD) is a biotechnology company focused on developing therapies to treat human disease. SUDA’s two focus areas are oncology and conditions that impact the central nervous system. SUDA is developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers. The Company is also developing low-risk oral sprays to reformulate existing pharmaceuticals. The potential benefits of administering drugs through the oral mucosa (i.e. cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA’s product pipeline includes an oral spray for the platelet-lowering drug anagrelide to treat metastatic disease in the background of high platelets, and ZolpiMist™, a first-in-class oral spray of zolpidem tartrate to treat short-term insomnia. ZolpiMist is approved by the FDA and the TGA and is marketed in the USA. SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.

For more information, visit [www.sudapharma.com](http://www.sudapharma.com)

This announcement contains certain statements which may constitute forward-looking statements or information (“forward-looking statements”), including statements regarding negotiations with third parties and regulatory approvals. These forward-looking statements are based on certain key expectations and assumptions, including assumptions regarding actions of third parties and financial terms. These factors and assumptions are based upon currently available information and the forward-looking statements contained herein speak only as of the date hereof. Although the expectations and assumptions reflected in the forward-looking statements are reasonable in the view of the Company’s directors and management, reliance should not be placed on such statements as there is no assurance that they will prove correct. This is because forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. These risks include, but are not limited to: uncertainties and other factors that are beyond the control of the Company; global economic conditions; risk associated with foreign currencies; and risk associated with securities market volatility. The Company assumes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements, except as required by Australian securities laws and ASX Listing Rules.